NEWS
FOCUS
VitroScreen was there!
VitroScreen was present to the second Microphysiological Systems (MPS) World Summit in Berlin and [...]
VitroScreen Seminar on Substance Based Medical Devices
Milan, 9th February 2023
VitroScreen has been a pioneer in developing and proposing pre-clinical experimental protocols on 3D [...]
VitroScreen has partecipated to IFSCC 2022 in London
A research study entitled Vascularized Dermopapilla 3D scaffold free Spheroids: an advanced micro-physiological system [...]
FOCUS 02.22 – VitroScreen Advanced Wound Healing model
In April 2022 the project EUROSTARS E! 113238 - LYSE-EFEKT ended: it has been [...]
FOCUS 01.22 – VitroScreen’s Histomorphology Platform
has a New Tool
The “TOP VIEW” is a new procedure that has been optimized in our Laboratory and [...]
FOCUS 05.21 – SenzaGen and VitroScreen join forces
SenzaGen and VitroScreen has decided to join forces. The highly accurate and broadly applicable [...]
FOCUS 04.21 – VitroScreen 20th anniversary
On May 21th 2021 VitroScreen’s team celebrated its 20th anniversary: it has been a [...]
FOCUS 03.21 – CIR AGREEMENT RENEWAL
La Ministre de l’Enseignement supérieur, de la Recherche et de l’Innovation vient d’accorder à [...]
FOCUS 02.21 – Food Supplements Pre-clinical Testing Platform
VitroScreen has developed a precise, sensitive and quantitative approach to define the mechanisms of action [...]
FOCUS 01.21 – Welcome ISO 10993-23!
VitroScreen supports the Medical Devices (MD) industry providing bio-compatibility studies for all MD classes [...]
FOCUS 08.20 – VitroScreen Season’s Greetings
Approaching the end of 2020, in the midst of a new social and economic [...]
-
FOCUS 07.20 – VitroScreen has signed an Agency Agreement with Takis Foustanos & CO with the aim of expanding its presence in Greece, Turkey, Cyprus and BulgariaFOCUS 07.20 – VitroScreen has signed an Agency Agreement with Takis Foustanos & CO with the aim of expanding its presence in Greece, Turkey, Cyprus and Bulgaria
FOCUS 07.20 – VitroScreen has signed an Agency Agreement with Takis Foustanos & CO with the aim of expanding its presence in Greece, Turkey, Cyprus and Bulgaria
Marisa Meloni, VitroScreen’s CEO commenting the agreement said: “We are particularly proud of this commercial partnership that will [...]
FOCUS 06.20 – VitroScreen’s interview on Corriere della sera 9.11.2020
In the page dedicated to New Biotechnologies Marisa Meloni, VitroScreen’s CEO, presents VitroScreen’s activities [...]
FOCUS 05.20 – Restyling VitroScreen’s Website
A new approach to share our engagement to innovation in pre-clinical testing In [...]
FOCUS 04.20 – ECHA UPDATE ON ALTERNATIVES
VitroScreen mission is to provide industrial partners with the most predictive, robust, biologically [...]
FOCUS 03.20 – VITROSCREEN’S IN VITRO CONSULTANCY UNIT
VitroScreen is proud to announce the establishment of the In vitro Consultancy Unit with [...]
FOCUS 02.20 – FACING COVID-19 AT WORK
At VitroScreen we are taking this challenge extremely seriously: firstly in the interest of [...]